The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
Research Funding - MedImmune
Travel, Accommodations, Expenses - MedImmune
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.
 
Johanna C. Bendell
No Relationships to Disclose
 
Vijay Reddy
Employment - Janssen Scientific Affairs; MedImmune
Stock and Other Ownership Interests - Johnson & Johnson; MedImmune
 
Fatemeh Tavakkoli
No Relationships to Disclose
 
Ching Ching Leow
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
 
Xia Li
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - MedImmune
 
Rakesh Kumar
Employment - GlaxoSmithKline; MedImmune
Stock and Other Ownership Interests - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
 
John H. Strickler
Consulting or Advisory Role - Amgen; Bayer; Bayer/Onyx; Boehringer Ingelheim; Celgene; Genentech/Roche; Marval Biosciences; Onyx
Research Funding - Abbvie (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); MedImmune (Inst); MethylGene (Inst); OncoMed (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst)